• Bristol-Myers Squibb Co., of New York, reported at the European Association for the Study of the Liver meeting in Berlin, that in a Phase II trial of daclatasvir and asunaprevir in difficult-to-treat genotype 1b hepatitis C patients, 77 percent of subjects achieved undetectable viral load at 24 weeks post-treatment (SVR24).
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST